News | June 03, 2026
Eurofragance and MartiDerm launch free skincare line to tackle 'fish odor syndrome'
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
The filing is backed by Phase III data from the lidERA Breast Cancer study
The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) single-dose vials is the bioequivalent to the reference listed drug (RLD) Halaven injection of Eisai, Inc.
The transaction includes an upfront payment of $1.55 billion, along with up to $1.1 billion in regulatory and commercial milestone payments
First-in-class treatment of life-threatening, drug-resistant Acinetobacter baumannii infections advancing toward Phase II clinical proof-of-concept
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
The safety profile was described as manageable, though not without notable toxicities
While overall survival data remain immature, the results pointed to a favourable trend.
Acquisition provides direct access to the Dutch healthcare market, enhancing Marksans’ sales, distribution and market-access capabilities across regulated European markets
Subscribe To Our Newsletter & Stay Updated
